Abstract
Intestinal efflux pumps such as P-glycoprotein play a significant role in altering the absorption of a wide range of drugs. Anticancer agents, antibiotics, antivirals, calcium channel blockers, immunosuppressive agents, peptide drugs and several other therapeutic compounds have been reported to be substrates of one or more transmembrane efflux transporters.
Inhibition of these efflux pumps by various compounds can lead to enhanced absorption of several drugs across the intestine.
In this chapter, several efflux pump inhibitors such as low molecular mass inhibitors, polymeric inhibitors and advanced formulation approaches on how to overcome drug efflux are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Shawi M.K., Urbatsch I.L., Senior A.E. (1994) Covalent inhibitors of P-glycoprotein ATPase activity, J Biol Chem 269(12):8986–8992.
Balayssac D., Authier N., Cayre A., Coudore F. (2005) Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett, 156(3):319–329.
Bardelmeijer H.A., Beijnen J.H., Brouwer K.R., Rosing H., Nooijen W.J., Schellens J.H., van Tellingen O. (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res, 6:4416–4421.
Batrakova E.V., Han H.Y., Alakhov V.Y., Miller D.W., Kabanov A.V. (1998) Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res, 15(6):850–855.
Bogman K., Zysset Y., Degen L., Hopfgartner G., Gutmann H., Alsenz J., Drewe J. (2005) P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin Pharmacol Ther, 77(1):24–32.
Carreno-Gomez B. and Duncan R. Compositions with enhanced oral bioavailability. US patent, 2002.
Choi J.S. and Jo B.W. (2004) Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm, 280:221–722.
Collnot E.M., Baldes C., Wempe M.F., Hyatt J., Navarro L., Edgar K.J., Schaefer U.F., Lehr C.M. (2006) Influence of vitamin E TPGS poly(ethlyene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release, 111:35–40.
Fisher M., Abramov M., Van Aerschot A., Xu D., Juliano R.L., Herdewijn P. (2007) Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res, 35(4):1064–1074.
Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts J.P., Hebert M.F. (2001) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther, 62:41–49.
Föger F., Hoyer H., Kafedjiiski K., Thaurer M., Bernkop-Schnürch A. (2006a) In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials, 27, (34), 5855–5860.
Föger F., Kafedjiiski K., Hoyer H., Loretz B., Bernkop-Schnürch A. (2006b) Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J Drug Targ, 15, (2), 132–139.
Föger, F., Schmitz T. and Bernkop-Schnürch A. (2006c) In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials, 27, (23), 4250–4255.
Föger F., Malaivijitnond S., Wannaprasert T., Huck C., Bernkop-Schnürch A., Werle M. (2008) Effect of oral paclitaxel in presence of a thiolated polymer on absorption and tumor growth in rats. J Drug Targeting, 16, (2), 149–55.
Germann U.A., Shlyakhter D., Mason V.S., Zelle R.E., Duffy J.P., Galullo V., Armistead D.M., Saunders J.O., Boger J., Harding M.W. (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs, 8:125–140.
Gerrard G., Payne E., Baker R.J., Jones D.T., Potter M., Prentice H.G. (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukaemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine, Haematologica 89:782–790.
Grabovac V., Bernkop-Schnürch A. (2006) Thiolated polymers as effective inhibitors of intestinal Mrp2 efflux pump transporters. Sci Pharm, 74.
Hugger E.D., Audus K.L., and Borchardt R.T. (2002) Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci, 91:1980–1990.
Hunter J., Hirst B.H. (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption, Adv Drug Deliv Rev 25:129–157.
Jain R., Majumdar S., Nashed Y., Pal D., Mitra A.K. (2004) Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol Pharm, 1(4):290–299.
Jain R., Duvvuri S., Kansara V., Mandava N.K., Mitra A.K. (2007) Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int J Pharm, 336: 233–240.
Johnson B.M., Charman W.N., Porter C.J.H. (2002) An in vitro examination of the impact of polyehtylene glycol 400, pluronic P85 and vitamin E D-a-tocopheryl polyethylene glycol 1000 succinate on p-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci, 4: 1–13.
Kim R.B. (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers, Drug Metab Rev, 34:47–54.
Kimura Y., Aoki J., Kohno M., Ooka H., Tsuruo T., Nakanishi O. (2002) P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol, 49:322–328.
Kuppens I.E., Bosch T.M., van Maanen M.J., Rosing H., Fitzpatrick A., Beijnen J.H., Schellens J.H. (2005) Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol, 55:72–78.
Lacombe O., Woodley J., Solleux C., Delbos J.M., Boursier-Neyret C., Houin G. (2004) Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. Eur J Pharm Sci, 23:385–391.
Lennernas H. (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet, 42:1141–1160.
Leu B.L., Huang J.D. (1995) Inhibition of intestinal Pglycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol, 35:432–436.
Lin Y., Shen Q., Katsumi H., Okada N., Fujita T., Jiang X., Yamamoto A. (2007) Effects of Labrasol and Other Pharmaceutical Excipients on the Intestinal Transport and Absorption of Rhodamine123, a P-Glycoprotein Substrate, in Rats. Biol Pharm Bull, 30(7) 1301–1307.
Liu C., Wu J., Shi B., Zhang Y., Gao T., Pei Y. (2006) Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm, 32:115–123.
Lo Y.L. (2003) Relationships between the hydrophilic–lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release, 90:37–48.
Malingre M.M., Ten Bokkel Huinink W.W., Mackay M., Schellens J.H., Beijnen J.H. (2001) Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol, 57:305–307.
Palmberger T.F., Hombach J., Bernkop-Schnürch A. (2008) Thiolated chitosan: Development and in vitro evaluation of an oral delivery system for acyclovir. Int J Pharm, 348(1–2):79–85.
Shen Q., Lin Y., Handa T., Doi M., Sugie M., Wakayama K., Okada N., Fujita T., Yamamoto A. (2006) Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm, 313:49–56.
Shono Y., Nishihara H., Matsuda Y., Furukawa S., Okada N., Fujita T., Yamamoto A. (2004) Modulation of intestinal P- glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci, 93:877–885.
Twentyman P.R., Bleehen N.M. (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer, 27:1639–1642.
van Asperen J., van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., Beijnen J.H. (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer, 76:1181–1183.
Varma M.V., Ashokraj Y., Dey C.S., Panchagnula R. (2003) P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res, 48:347–359.
Varma M.V., Panchagnula R. (2005) Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci, 25:445–453.
Varma M.V., Perumal O.P., Panchagnula R. (2006) Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol, 10:367–373.
Werle M., Hoffer M. (2006) Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Rel, 111, (1–2), 41–46.
Werle M. (2008a) Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery. J Pharm Sci, 97, (1), 60–70.
Werle M. (2008b) Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res, 25, (3), 500–11.
Woo J.S., Lee C.H., Shim C.K., Hwang S.J. (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res, 20:24–30.
Yumoto R., Murakami T., Nakamoto Y., Hasegawa R., Nagai J., Takano M. (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther, 289:149–155.
Zhang H., Yao M., Morrison R.A., Chong S. (2003) Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res, 26:768–772.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Föger, F. (2009). Strategies to Overcome Efflux Pumps. In: Bernkop-Schnürch, A. (eds) Oral Delivery of Macromolecular Drugs. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0200-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0200-9_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0199-6
Online ISBN: 978-1-4419-0200-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)